Literature DB >> 15108804

Therapeutic implications of cancer stem cells.

Muhammad Al-Hajj1, Michael W Becker, Max Wicha, Irving Weissman, Michael F Clarke.   

Abstract

Most cancers comprise a heterogenous population of cells with marked differences in their proliferative potential as well as the ability to reconstitute the tumor upon transplantation. Cancer stem cells are a minor population of tumor cells that possess the stem cell property of self-renewal. In addition, dysregulation of stem cell self-renewal is a likely requirement for the development of cancer. This new model for cancer will have significant ramifications for the way we study and treat cancer. In addition, through targeting the cancer stem cell and its dysregulated self-renewal, our therapies for treating cancer are likely to improve.

Entities:  

Mesh：

Year:  2004        PMID： 15108804     DOI： 10.1016/j.gde.2003.11.007

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  183 in total

Review 1.  Cancer stem cells: a novel paradigm for cancer prevention and treatment.

Authors:  Dharmalingam Subramaniam; Satish Ramalingam; Courtney W Houchen; Shrikant Anant
Journal:  Mini Rev Med Chem       Date:  2010-05       Impact factor: 3.862

Review 2.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Permanently blocked stem cells derived from breast cancer cell lines.

Authors:  Gangadharan B Sajithlal; Kristi Rothermund; Fang Zhang; David J Dabbs; Jean J Latimer; Stephen G Grant; Edward V Prochownik
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

Review 4.  Cervical cancer stem cells.

Authors:  Tingting Yao; Rongbiao Lu; Yizhen Zhang; Ya Zhang; Chenyang Zhao; Rongchun Lin; Zhongqiu Lin
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

5.  Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo; Jiang F Zhong; William G Loudon
Journal:  World J Stem Cells       Date:  2011-09-26       Impact factor: 5.326

6.  MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Authors:  Chandra Bartholomeusz; Xuemei Xie; Mary Kathryn Pitner; Kimie Kondo; Ali Dadbin; Jangsoon Lee; Hitomi Saso; Paul D Smith; Kevin N Dalby; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2015-09-17       Impact factor: 6.261

7.  A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?

Authors:  Alireza Mirzaei; Gholamreza Tavoosidana; Afshin Abdi Rad; Farhad Rezaei; Masoumeh Tavakoli-Yaraki; Azade Amini Kadijani; Ehsan Khalili; Zahra Madjd
Journal:  Tumour Biol       Date:  2015-09-17

8.  HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

Authors:  Nadire Duru; Ming Fan; Demet Candas; Cheikh Menaa; Hsin-Chen Liu; Danupon Nantajit; Yunfei Wen; Kai Xiao; Angela Eldridge; Brett A Chromy; Shiyong Li; Douglas R Spitz; Kit S Lam; Max S Wicha; Jian Jian Li
Journal:  Clin Cancer Res       Date:  2012-10-22       Impact factor: 12.531

9.  UM-SCC-103: a unique tongue cancer cell line that recapitulates the tumorigenic stem cell population of the primary tumor.

Authors:  John H Owen; Samantha J Hauff; Alice L Tang; Martin P Graham; Michael J Czerwinski; Marcella Kaddoura; Silvana Papagerakis; Carol R Bradford; Thomas E Carey; Mark E P Prince
Journal:  Ann Otol Rhinol Laryngol       Date:  2014-05-09       Impact factor: 1.547

10.  Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer.

Authors:  Min Hye Jang; Hyun Jong Kang; Ki Seok Jang; Seung Sam Paik; Wan Seop Kim
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.